VennVax, a DNA-prime, peptide-boost multi-T-cell epitope poxvirus vaccine, induces protective immunity against vaccinia infection by T cell response alone.

The potential for smallpox to be disseminated in a bioterror attack has prompted development of new, safer smallpox vaccination strategies. We designed and evaluated immunogenicity and efficacy of a T-cell epitope vaccine based on conserved and antigenic vaccinia/variola sequences, identified using bioinformatics and immunological methods. Vaccination in HLA transgenic mice using a DNA-prime/peptide-boost strategy elicited significant T cell responses to multiple epitopes. No antibody response pre-challenge was observed, neither against whole vaccinia antigens nor vaccine epitope peptides. Remarkably, 100% of vaccinated mice survived lethal vaccinia challenge, demonstrating that protective immunity to vaccinia does not require B cell priming.

[1]  Carlos J. Camacho,et al.  Structural and Thermodynamic Approach to Peptide Immunogenicity , 2008, PLoS Comput. Biol..

[2]  J. Nyhus,et al.  HLA- and dose-dependent immunogenicity of a peptide-based HIV-1 immunotherapy candidate (Vacc-4x) , 2004, AIDS.

[3]  D. Molina,et al.  An Extremely Diverse CD4 Response to Vaccinia Virus in Humans Is Revealed by Proteome-Wide T-Cell Profiling , 2008, Journal of Virology.

[4]  J. Breman,et al.  Poxvirus dilemmas--monkeypox, smallpox, and biologic terrorism. , 1998, The New England journal of medicine.

[5]  Aaron J. Johnson,et al.  Cellular and Humoral Immunity against Vaccinia Virus Infection of Mice 1 , 2004, The Journal of Immunology.

[6]  D. Montefiori,et al.  Immune Control of an SIV Challenge by a T Cell-Based Vaccine in Rhesus Monkeys , 2008, Nature.

[7]  D A Henderson,et al.  The looming threat of bioterrorism. , 1999, Science.

[8]  M. Bevan.  Helping the CD8+ T-cell response , 2004, Nature Reviews Immunology.

[9]  P. Earl,et al.  Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus , 2008, Proceedings of the National Academy of Sciences.

[10]  L. Stern,et al.  Human CD4+ T Cell Epitopes from Vaccinia Virus Induced by Vaccination or Infection , 2007, PLoS pathogens.

[11]  A. D. De Groot,et al.  Epitope-based vaccination against pneumonic tularemia. , 2009, Vaccine.

[12]  J. Thornton,et al.  Continuous and discontinuous protein antigenic determinants , 1986, Nature.

[13]  J. Baisch,et al.  HLA-DRB 1 Polymorphism Determines Susceptibility to Autoimmune Thyroiditis in Transgenic Mice : Definitive Association with HLA-DRBI * 0301 ( DR 3 ) Gene , 2003 .

[14]  R. Jacobson,et al.  The immunology of smallpox vaccines , 2009, Current opinion in immunology.

[15]  S. Szu,et al.  Hypothesis: how licensed vaccines confer protective immunity. , 1996, Advances in experimental medicine and biology.

[16]  K. Abel,et al.  A heterologous DNA prime/protein boost immunization strategy for rhesus cytomegalovirus. , 2008, Vaccine.

[17]  J. Atwood,et al.  Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel☆ , 2003 .

[18]  K. Ishii,et al.  Sterically Stabilized Cationic Liposomes Improve the Uptake and Immunostimulatory Activity of CpG Oligonucleotides1 , 2001, The Journal of Immunology.

[19]  N. Langeland,et al.  Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy. , 2002, AIDS research and human retroviruses.

[20]  R. J. Reed,et al.  US military service members vaccinated against smallpox in 2003 and 2004 experience a slightly higher risk of hospitalization postvaccination. , 2008, Vaccine.

[21]  Magdalini Moutaftsi,et al.  Correlates of protection efficacy induced by vaccinia virus‐specific CD8+ T‐cell epitopes in the murine intranasal challenge model , 2009, European journal of immunology.

[22]  J. Killion,et al.  Direct comparison of ELISPOT and ELISA-based assays for detection of individual cytokine-secreting cells. , 1994, Lymphokine and cytokine research.

[23]  G. Hämmerling,et al.  HLA-DRB1 polymorphism determines susceptibility to autoimmune thyroiditis in transgenic mice: definitive association with HLA- DRB1*0301 (DR3) gene , 1996, The Journal of experimental medicine.

[24]  P. Jahrling,et al.  Countermeasures to the bioterrorist threat of smallpox. , 2005, Current molecular medicine.

[25]  S. Ostroff,et al.  Myopericarditis following smallpox vaccination among vaccinia-naive US military personnel. , 2003, JAMA.

[26]  C Crimi,et al.  Optimization of epitope processing enhances immunogenicity of multiepitope DNA vaccines. , 2001, Vaccine.

[27]  Anne S De Groot,et al.  HIV vaccine development by computer assisted design: the GAIA vaccine. , 2005, Vaccine.

[28]  R. Eisenberg,et al.  Dominance and Diversity in the Primary Human CD4 T Cell Response to Replication-Competent Vaccinia Virus1 , 2007, The Journal of Immunology.

[29]  V. Apostolopoulos,et al.  Design of peptide-based vaccines for cancer. , 2006, Current medicinal chemistry.

[30]  R. Buller,et al.  Human monkeypox: an emerging zoonotic disease. , 2007, Future microbiology.

[31]  I. M. Belyakov,et al.  Protection against Lethal Vaccinia Virus Challenge in HLA-A2 Transgenic Mice by Immunization with a Single CD8+ T-Cell Peptide Epitope of Vaccinia and Variola Viruses , 2004, Journal of Virology.

[32]  X. Mo,et al.  Induction of cytokines in mice with parainfluenza pneumonia , 1995, Journal of virology.

[33]  G. Karupiah,et al.  Antiviral protection following immunization correlates with humoral but not cell‐mediated immunity , 2010, Immunology and cell biology.

[34]  P. Earl,et al.  Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[35]  F. Ennis,et al.  Comparison of the safety and immunogenicity of ACAM1000, ACAM2000 and Dryvax in healthy vaccinia-naive adults. , 2009, Vaccine.

[36]  R. Buller,et al.  Highly attenuated smallpox vaccine protects rabbits and mice against pathogenic orthopoxvirus challenge. , 2006, Vaccine.

[37]  John Sidney,et al.  A Rational Strategy to Design Multiepitope Immunogens Based on Multiple Th Lymphocyte Epitopes1 , 2002, The Journal of Immunology.

[38]  Julie A McMurry,et al.  In silico-accelerated identification of conserved and immunogenic variola/vaccinia T-cell epitopes. , 2009, Vaccine.

[39]  M. Wick,et al.  TNF-α-Dependent and -Independent Maturation of Dendritic Cells and Recruited CD11cintCD11b+ Cells during Oral Salmonella Infection1 , 2005, The Journal of Immunology.

[40]  Lihan K. Yan,et al.  Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge. , 2007, Vaccine.

[41]  Magdalini Moutaftsi,et al.  A consensus epitope prediction approach identifies the breadth of murine TCD8+-cell responses to vaccinia virus , 2006, Nature Biotechnology.

[42]  Julie A McMurry,et al.  Diversity of Francisella tularensis Schu4 antigens recognized by T lymphocytes after natural infections in humans: identification of candidate epitopes for inclusion in a rationally designed tularemia vaccine. , 2007, Vaccine.